APRIL and BAFF, previously recognized as B cell modulators under normal settings, were hypothesized to play a role in supporting the survival of chronic lymphocytic leukemia (CLL) cells. This evidence concerns the gene TNFSF13B and B-cell chronic lymphocytic leukemia.